Navigation Links
Novel Technique Would Prevent Re-Clogged Arteries

Researchers at the Technion-Israel Institute of Technology are proposing a revolutionary approach to prevent the common post-balloon angioplasty problem// of restenosis (re-clogging of coronary arteries).

More than 1.2 million angioplasties were performed in the United States in 2003, according to the American Heart Association.

Angioplasty is a minimally invasive procedure, during which a tiny deflated balloon is inserted into clogged arteries and inflated to open blockages. In many cases, a stent – originally mounted on the balloon – is then positioned inside the artery, against the arterial wall. Blockages – caused not by new fatty deposits, but by tissue growth from the walls of the blood vessel – re-occur in more than one-third of patients. Such growths, which doctors relate to as they would a cancerous growth, are most often treated with “anti-proliferative” medications that prevent uncontrolled tissue growth.

Because of the site-specific nature of these growths, the drugs to treat them must be delivered only to the affected tissue. Stent manufacturers currently include such drugs in their products for slow release over a six-month period (during which time the risk for restenosis is highest). Precise control of this release process can be tricky, however, and restenosis still occurs in many patients.

The new, patented technique – developed in the Technion Department of Biomedical Engineering by Professor Noah Lotan, Dr. Sarit Sivan and Professor Uri Dinnar – begins when the patient swallows a "pro-drug" compound. Inactive by itself, this compound can be taken for as long as necessary without side effects. It is activated only when it comes into contact with a specific enzyme attached to the stent by its manufacturer. In effect, the enzyme on the stent then becomes a "pharmaceutical factory" that manufactures an active anti-proliferative drug.

According to lead researcher Lotan, the pro-drug is an amin o acid that is a safe and natural component of all proteins. When the risk of restenosis abates, patients could simply stop taking the pro-drug, and the stent would stop manufacturing the drug.

“This approach makes up a very general technological platform that can be applied for different medical problems,” said Lotan. “It has potential applications for every drug, known today or invented in the future, and could be useful for medications – including chemotherapy drugs – best administered to one very specific location in the body."

Source-Newwise
SRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... VIRGINIA (PRWEB) , ... April 25, 2017 , ... ... leading the way in unveiling cutting-edge birth defects research related to Zika virus ... by the world’s premier society for this important science. , The ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... ... The bar for just about everything—apparel, eyewear, cars and even phone cases—is ... and film stardom.(1) Not to be left out is that most desired of commodities, ... gamut from being encrusted with jewels and precious metals to, at the very least, ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... Calif. , April 24, 2017 SW ... grip, protection, and comfort, announces the release of the ... S8+. This most recent example of leading edge nitrile ... grip pattern for 200% more tactile grip on wet ... protection and durability. With TracTek and a suite of ...
(Date:4/21/2017)... Halo Labs announces the launch of a novel low ... Horizon at PEGS 2017 in Boston ... visible particulate matter in biopharmaceutical samples to enable for ... candidate selection and pre-formulation. Halo Labs is ... Elion Labs for system validation. "We are very ...
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
Breaking Medicine Technology: